Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
DeepCure
Utilizes deep learning and molecular simulations to discover small molecule drugs for challenging targets.
What they do
The platform combines artificial intelligence with automated chemistry to explore massive virtual chemical libraries. Biotech and pharma partners use the technology to identify and optimize therapeutic candidates for targets that were previously considered difficult to drug with small molecules.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Boston, United States
- Region
- North America
- Founded
- 2018
- Total funding
- $47M raised
Notable investors: Decheng Capital, Morningside Ventures, TLV Partners.
Also in Biotech & Pharma
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA